Eisai Co., Ltd. and Biogen Inc. introduced new information on the Alzheimer’s Association International Conference 2026 in London, revealing that the LEQEMBI (lecanemab) subcutaneous autoinjector formulation affords efficacy and security akin to intravenous administration for early Alzheimer’s illness therapy.
The information, introduced within the session titled “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations,” highlighted that the subcutaneous possibility offers a handy different to intravenous dosing. This might improve entry and supply of care throughout numerous healthcare settings.
Key findings from the lecanemab SC-AI improvement program confirmed that once-weekly 500 mg SC-AI achieved drug publicity much like the authorized IV routine (10 mg/kg each two weeks), with an publicity ratio of 104% (90% CI: 99.1%–109%). This helps the expectation of comparable scientific efficacy and security, impartial of the administration route.
The examine demonstrated constant outcomes throughout affected person populations, with bioequivalence achieved when it comes to amyloid removing and scientific efficacy. Patients can swap between IV and SC administration, providing higher flexibility. The security profile of SC-AI was in step with the IV formulation, with low incidence of anti-drug antibodies and no neutralizing antibodies noticed.
Real-world proof from two U.S. Alzheimer’s therapy facilities supported these findings. At one middle, 28 sufferers receiving SC administration confirmed slower cognitive decline over 36 months in comparison with a matched cohort. Another case collection indicated that 91% of sufferers confirmed enchancment or stability on MMSE scores with SC administration.
Patient and care associate surveys reported excessive satisfaction with subcutaneous LEQEMBI, with satisfaction charges between 75% to 97%, comfort scores from 83% to 97%, and willingness to suggest therapy starting from 92% to 100%.
Eisai leads the event and regulatory submissions for lecanemab globally, with co-commercialization and co-promotion efforts alongside Biogen.